AUGMENTIN 500

Compare AUGMENTIN 500  to:
Compare
Compare

Generic Name for AUGMENTIN 500

Amoxicillin 500mg, clavulanic acid (as potassium) 125mg; tabs.

Legal Classification:

Rx

Pharmacological Class for AUGMENTIN 500

Broad-spectrum penicillin + β-lactamase inhibitor.

Manufacturer of AUGMENTIN 500

GlaxoSmithKline Pharmaceuticals

Indications for AUGMENTIN 500

Susceptible infections including sinusitis due to β-lactamase producing organisms, otitis media, lower respiratory or skin and skin structure infections, UTIs.

Adult dose for AUGMENTIN 500

Take with meals. Base dose on amoxicillin component. Due to clavulanic acid component, two 250mg tabs are not equivalent to one 500mg tab. May use 125mg/5mL or 250mg/5mL susp in place of 500mg tab; or 200mg/5mL or 400mg/5mL susp in place of 875mg tab. Severe infections or respiratory tract infections: 875mg every 12 hrs or 500mg every 8 hrs. Others: 500mg every 12 hrs or 250mg every 8 hrs. Renal impairment: CrCl<30mL/min: do not use 875mg tabs. CrCl: 10–30mL/min: 250–500mg every 12 hrs. CrCl<10mL/min: 250mg–500mg every 24 hrs; hemodialysis: give additional doses during and after dialysis.

Children's dosing for AUGMENTIN 500

Take with meals. Base dose on amoxicillin component. <12 weeks: 30mg/kg/day in 2 divided doses every 12 hrs (use 125mg/5mL). ≥12 weeks: Twice-daily regimen: use 200mg/5mL or 400mg/5mL. Three times daily regimen: use 125mg/5mL or 250mg/5mL. Less severe infections: 25mg/kg/day in 2 divided doses every 12 hrs or 20mg/kg/day in 3 divided doses every 8 hrs. Others: 45mg/kg/day in 2 divided doses every 12 hrs or 40mg/kg/day in 3 divided doses every 8 hrs. ≥40kg: see Adult dose.

Also:

Contraindications for AUGMENTIN 500

History of Augmentin-associated cholestatic jaundice/hepatic dysfunction. XR: Severe renal impairment (CrCl <30mL/min) or hemodialysis.

Warnings/Precautions for AUGMENTIN 500

Cephalosporin, imipenem, or other allergy: not recommended. Monitor blood, renal, and hepatic function in long-term use. Hepatic dysfunction. Mononucleosis. Elderly (consider monitoring renal function). Labor & delivery. Pregnancy (Cat.B). Nursing mothers.

Interactions for AUGMENTIN 500

May cause false (+) glucose test with Clinitest, Benedict's or Fehling's soln. Probenecid potentiates amoxicillin.

Adverse Reactions for AUGMENTIN 500

Diarrhea, nausea, abdominal pain, rash, urticaria, vomiting, vaginitis, anaphylaxis.

How is AUGMENTIN 500 supplied?

XR tabs—28, 40
Tabs 250mg—30
Tabs 500mg, 875mg—20
Susp 125mg/5mL, 250mg/5mL—75mL, 100mL, 150mL
Susp 200mg/5mL, 400mg/5mL—50mL, 75mL, 100mL
Chew tabs 125mg, 250mg—30
Chew tabs 200mg, 400mg—20
Susp ES-600 600mg/5mL—50mL, 75mL, 100mL, 125mL, 150mL, 200mL

Related Disease:

Infections, bacterial~systemic antiinfectives
Sinusitis

Related Resources

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions